Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jana, Krieger"'
Autor:
Katja Stifter, Cornelia Schuster, Jana Krieger, Andreas Spyrantis, Bernhard Otto Boehm, Reinhold Schirmbeck
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss , Pp 123-133 (2019)
DNA vaccines against autoimmune type 1 diabetes (T1D) contain a nonpredictable risk to induce autoreactive T cell responses rather than a protective immunity. Little is known if (and how) antigen expression and processing requirements favor the induc
Externí odkaz:
https://doaj.org/article/7003fd9174b24d7ea239d6e5ed26751e
Autor:
Johann Gout, Thomas Seufferlein, Alexander Kleger, Katja Stifter, Jana Krieger, Leonie Ruths, Medhanie Mulaw, Andre Lechel, Martin Wagner, Reinhold Schirmbeck
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Many cancer cells express a major histocompatibility complex class I low/ programmed cell death 1 ligand 1 positive (MHC-Ilo/PD-L1+) cell surface profile. For immunotherapy, there is, thus, an urgent need to restore presentation competence
Externí odkaz:
https://doaj.org/article/9f600427fb834004b88c2d0fedc55b38
Autor:
Katja Stifter, Thomas Seufferlein, Jana Krieger, Alain Tissot, Iryna Dekhtiarenko, Reinhold Schirmbeck, Martin Wagner
Publikováno v:
Vaccine. 38:3711-3719
Somatic mutations in tumors often generate neoproteins that contain MHC-I-binding neoepitopes. Little is known if and how efficient tumor-specific neoantigens activate CD8+ T cells. Here, we asked whether a de novo generated neoepitope, encoded eithe
Fit nach der Geburt und ein zufriedenes Baby - das wünschen sich Mütter, Väter und Großeltern. Keine Zeit für das Fitnessstudio, keine Geräte zuhause? Das Kind will geknuddelt, bewegt oder beruhigt werden? Lassen Sie sich ein auf Übungen, mit
Autor:
Katja, Stifter, Jana, Krieger, Leonie, Ruths, Johann, Gout, Medhanie, Mulaw, Andre, Lechel, Alexander, Kleger, Thomas, Seufferlein, Martin, Wagner, Reinhold, Schirmbeck
Publikováno v:
Journal for Immunotherapy of Cancer
Background Many cancer cells express a major histocompatibility complex class I low/ programmed cell death 1 ligand 1 positive (MHC-Ilo/PD-L1+) cell surface profile. For immunotherapy, there is, thus, an urgent need to restore presentation competence
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports
Scientific Reports
The HBV core protein self-assembles into particles and encapsidates immune-stimulatory bacterial RNA through a cationic COOH-terminal (C150–183) domain. To investigate if different cationic domains have an impact on the endogenous RNA-binding of HB
Publikováno v:
Cellular and Molecular Immunology
Autor:
Katja, Stifter, Iryna, Dekhtiarenko, Jana, Krieger, Alain Charles, Tissot, Thomas, Seufferlein, Martin, Wagner, Reinhold, Schirmbeck
Publikováno v:
Vaccine. 38(21)
Somatic mutations in tumors often generate neoproteins that contain MHC-I-binding neoepitopes. Little is known if and how efficient tumor-specific neoantigens activate CD8
Autor:
Andreas Spyrantis, Bernhard O. Boehm, Cornelia Schuster, Reinhold Schirmbeck, Katja Stifter, Jana Krieger
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss, Pp 123-133 (2019)
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss, Pp 123-133 (2019)
DNA vaccines against autoimmune type 1 diabetes (T1D) contain a nonpredictable risk to induce autoreactive T cell responses rather than a protective immunity. Little is known if (and how) antigen expression and processing requirements favor the induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65cd2cc0263883468ff3c6b59ae6843c
http://hdl.handle.net/10220/48490
http://hdl.handle.net/10220/48490
Autor:
Alexander Kleger, Jana Krieger, Thomas Seufferlein, Martin Wagner, Katja Stifter, Reinhold Schirmbeck, André Lechel, Medhanie A. Mulaw, Johann Gout, Leonie Ruths
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundMany cancer cells express a major histocompatibility complex class I low/ programmed cell death 1 ligand 1 positive (MHC-Ilo/PD-L1+) cell surface profile. For immunotherapy, there is, thus, an urgent need to restore presentation competence